Click: http://www.guidechem.com/cas-856/85622-93-1.

html 1

for suppliers of this product

The future of Temozolomide Temozolomide, 85622-93-1, guidechem Temozolomide is a white to light tan/light pink powder with a molecular formula of C6H6N6O2 and a molecular weight of 194.15. The molecule is stable at acidic pH ( < 5) and labile at pH > 7; hence TEMODAR can be administered orally and intravenously. The prodrug, temozolomide, is rapidly hydrolyzed to the active 5-(3-methyltriazen-1-yl) imidazole-4-carboxamide (MTIC) at neutral and alkaline pH values, with hydrolysis taking place even faster at alkaline pH. Temozolomide(CAS NO:85622-93-1) is now used worldwide to treat the most common adult brain tumour, called glioblastoma, as well as some other types. In combination with radiotherapy, it has become the international standard-of-care for thousands of people with this type of cancer. Laboratory studies and clinical trials are investigating whether it might be possible to further increase the anticancer potency of temozolomide by combining it with other pharmacologic agents. For example, clinical trials have indicated that the addition of chloroquine might be beneficial for the treatment of glioma patients. In laboratory studies, it was found that temozolomide killed brain tumor cells more efficiently when epigallocatechin gallate (EGCG), a component of green tea, was added; however, the efficacy of this effect has not yet been confirmed in brain tumor patients. More recently, use of the novel oxygen diffusion-enhancing compound trans sodium crocetinate (TSC) when combined with this medicine and radiation therapy has been investigated in preclinical studies and a clinical trial is currently underway. Cancer Research UK scientists led the development of temozolomide. From early pioneering lab work, to the discovery, development and first clinical trials of the drug in people with cancer, our researchers were involved every step of way. The undisputed father of temozolomide is Malcolm Stevens, now Emeritus Professor at the University of Nottingham.We spoke to him to find out more about this medicine and its future fate. Worldwide sales of temozolomide have now reached 1 billion dollars. Because of our partnership with Schering-Plough, we receive a royalty on this. The money is ploughed straight back into our research, funding new work into the prevention, diagnosis and treatment of cancer. But the story of temozolomide doesnt end here. The drug continues to benefit more and more people each year---people like Parminder, who was diagnosed with a brain tumour in 2011, when she was just 28. She had surgery and radiotherapy, as well as two courses of this medicine, and it looks like her tumour is gone for now. As well as being back on her feet (last year she ran Race For Life to support our research) shes now back at work as an advertising sales executive.

Personally, I found it was a hard course of treatment to have, but I am glad to have got through it, she says. I am so grateful for the treatment that I had and I think it is fantastic how organisations like Cancer Research UK are working on developing these treatments for the future. For now Parminder is doing well, and were all keeping our fingers crossed that things stay that way. And for many thousands of people around the world going through treatment for brain tumours, temozolomide is playing a vital role in the treatment that is helping to control their disease, giving them precious months, years and even decades more with their families. Our scientists are now testing whether the drug can be used for other types of cancer, and continue to refine how its used to treat patients through clinical trials. This includes OPARATIC, an important trial testing temozolomide in combination with new drugs called PARP inhibitors for glioblastoma. This trial, and others like it, could bring important benefits to many more people in future. The discovery and development of temozolomide would not have been possible without the support of the public and with your continued support, well be able to carry on developing the life-saving treatments of tomorrow. Want to learn more information about temozolomide, you can access the guidechem.com. Guidechem.com is just a place for you to look for some chemicals.